TW200637816A - Substituted indole compound - Google Patents
Substituted indole compoundInfo
- Publication number
- TW200637816A TW200637816A TW095112078A TW95112078A TW200637816A TW 200637816 A TW200637816 A TW 200637816A TW 095112078 A TW095112078 A TW 095112078A TW 95112078 A TW95112078 A TW 95112078A TW 200637816 A TW200637816 A TW 200637816A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- group
- alkyl group
- substituted alkyl
- heterocycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides an excellent LXR modulator. The present invention provides a compound of the following formula (I): [wherein, R1, R2, R3, R4: H, an optionally substituted alkyl group, OH, an optionally substituted alkoxy group, an optionally substituted amino group, a halogen, a phenyl group, etc; R5: H, an alkyl group; R6: -COR8(wherein, R8: an optionally substituted alkoxy group, an optionally substituted phenoxy group, an optionally substituted amino group, etc), -SO2R9(wherein, R9: an optionally substituted alkyl group, an optionally substituted phenyl group, an optionally substituted heterocycle group), an optionally substituted alkyl group; R7: -X2R10[wherein, R10: -COR11(wherein, R11:OH, an optionally substituted alkoxy group, an optionally substituted amino group), -SO2R12(wherein, R12: an optionally substituted alkyl group, an optionally substituted amino group), -N(R13)COR14(wherein, R13: H, an optionally substituted alkyl group; R14: H, an optionally substituted alkyl group), -N(R13)SO2R15(wherein, R13: definition as above; R15: an optionally substituted alkyl group), a tetrazol-5-yl group; X2: a single bond, an optionally substituted alkylene group]; X1: an optionally substituted methylene group; Y1: an optionally substituted phenyl group, an optionally substituted heterocycle group; Y2: an optionally substituted aryl group, an optionally substituted heterocycle group] compound, etc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005110908 | 2005-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200637816A true TW200637816A (en) | 2006-11-01 |
Family
ID=37086912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095112078A TW200637816A (en) | 2005-04-07 | 2006-04-06 | Substituted indole compound |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW200637816A (en) |
| WO (1) | WO2006109633A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112689630A (en) * | 2018-06-28 | 2021-04-20 | 菲尼克斯-Fxr股份有限公司 | Novel LXR modulators with bicyclic core moieties |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2187883A2 (en) * | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| BR112013005425A2 (en) | 2010-09-07 | 2018-05-02 | Snu R&Db Foundation | Three master teopin compounds and uses of these materials |
| JP6378630B2 (en) | 2012-03-02 | 2018-08-22 | ラレキサー セラピューティクス，インク | Liver X receptor (LXR) modulators for the treatment of skin diseases, disorders, and abnormalities |
| PT3041835T (en) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Liver x receptor (lxr) modulators |
| JP2016532713A (en) | 2013-09-04 | 2016-10-20 | アレクサー セラピューティクス， インク． | Liver X receptor (LXR) modulator |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| CA2980394A1 (en) | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| CN109069461A (en) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | The treatment method of illness relevant to marrow source property inhibition cell |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| CN114728875A (en) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | Metal salts and their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10508321A (en) * | 1995-09-01 | 1998-08-18 | イーライ・リリー・アンド・カンパニー | Indolyl neuropeptide Y receptor antagonist |
| WO1998008818A1 (en) * | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| IL137540A0 (en) * | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
| US20040072868A1 (en) * | 2000-09-18 | 2004-04-15 | Collins Jon Loren | Substitued aminopropoxyaryl derivatives useful as agonists for lxr |
| EP1513534A2 (en) * | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| WO2003106435A1 (en) * | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| JP2006001926A (en) * | 2004-05-20 | 2006-01-05 | Sankyo Co Ltd | Indole compound |
| EP1764075A4 (en) * | 2004-07-02 | 2010-08-04 | Sankyo Co | Tissue factor production inhibitor |
-
2006
- 2006-04-05 WO PCT/JP2006/307187 patent/WO2006109633A1/en active Application Filing
- 2006-04-06 TW TW095112078A patent/TW200637816A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112689630A (en) * | 2018-06-28 | 2021-04-20 | 菲尼克斯-Fxr股份有限公司 | Novel LXR modulators with bicyclic core moieties |
| US11970484B2 (en) | 2018-06-28 | 2024-04-30 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006109633A1 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200637816A (en) | Substituted indole compound | |
| TW200619191A (en) | Phenyl compounds with more than 2 substitutes | |
| TW200606133A (en) | Substituted benzene compounds | |
| TW200602320A (en) | Indol compounds | |
| UA105185C2 (en) | Pyrrols | |
| IN2012DN04853A (en) | ||
| MY147316A (en) | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase | |
| MX2011013764A (en) | Novel conjugates, preparation thereof, and therapeutic use thereof. | |
| CO6241190A2 (en) | ENZYMATIC INHIBITION COMPOUNDS | |
| TN2009000024A1 (en) | Prodrug of cinnamide compound | |
| IN2014CN00613A (en) | ||
| MX2009010962A (en) | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound. | |
| WO2009156861A8 (en) | Substituted pyrimidone derivatives | |
| HK1128283A1 (en) | Aminophenyl derivatives as novel inhibitors of histone deacetylase | |
| MX2009006907A (en) | Glucokinase-activating substance. | |
| TW200609223A (en) | Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives | |
| TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
| EA200870191A1 (en) | NEW CYCLIC UREA DERIVATIVES, THEIR RECEPTION AND PHARMACEUTICAL APPLICATION AS KINAZ INHIBITORS | |
| RS52900B (en) | Benzoylpyrazole compounds, process for their production and herbicides containing them | |
| JO2704B1 (en) | Inhibitors of the interaction between mdm2 and p53 | |
| MY148900A (en) | Preparation process of latent catalyst and epoxy resin composition | |
| TW200631939A (en) | Process for cross coupling indoles | |
| MY160882A (en) | Biocidal composition and method | |
| TNSN08161A1 (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof | |
| MY145368A (en) | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |